PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Prelude Therapeutics for potential violations of securities laws following a significant drop in share price after the company paused its SMARCA2 degrader program [1][2]. Group 1: Investigation Details - The investigation centers on whether Prelude issued false or misleading statements or failed to disclose important information to investors [2]. - Prelude announced the pause of its SMARCA2 degrader program on November 4, 2025, citing a comprehensive review of clinical data and resource allocation considerations [2]. - Following the announcement, Prelude's shares fell by approximately 55.8% on the same day [2]. Group 2: Company Information - Prelude Therapeutics is listed on NASDAQ under the ticker PRLD [1]. - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].